GlassScriptPhysician profile
George W Mathews
NPI 1619980919
$8,337.61
in general payments reported to CMS, 2019-2025
43 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $632 · 2021: $630 · 2022: $1,412 · 2023: $1,639 · 2024: $2,020 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,852.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,713.66 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $998.45 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $838.10 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Alkermes, INC. | $606.95 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $604.00 | 2020-2025 | Caplyta |
| Lilly USA, LLC | $431.39 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Sunovion Pharmaceuticals INC. | $402.28 | 2019-2022 | |
| Axsome Therapeutics, INC. | $397.16 | 2022-2024 | Auvelity |
| Novo Nordisk INC | $350.59 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $310.68 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $243.69 | 2019-2022 | |
| Lundbeck LLC | $210.91 | 2022-2023 | Rexulti, Brintellix |
| Astrazeneca Pharmaceuticals LP | $129.39 | 2021-2024 | Farxiga, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $125.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $120.31 | 2022-2024 | Gvoke Hypopen |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.